Fmr LLC Sells 472,732 Shares of Glaukos Co. (NYSE:GKOS)

FMR LLC reduced its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,111,756 shares of the medical instruments supplier's stock after selling 472,732 shares during the period. FMR LLC owned approximately 11.08% of Glaukos worth $916,397,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its holdings in shares of Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after buying an additional 73 shares in the last quarter. Mutual of America Capital Management LLC grew its position in Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after acquiring an additional 89 shares during the last quarter. HighTower Advisors LLC raised its stake in Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after acquiring an additional 91 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after acquiring an additional 100 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in shares of Glaukos by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock valued at $2,204,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Remove Ads

Glaukos Stock Up 0.4 %

Shares of GKOS traded up $0.39 during trading hours on Friday, reaching $90.05. 533,122 shares of the stock traded hands, compared to its average volume of 630,903. The stock has a fifty day simple moving average of $114.19 and a 200 day simple moving average of $132.69. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52 week low of $77.91 and a 52 week high of $163.71. The company has a market cap of $5.09 billion, a price-to-earnings ratio of -31.38 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, equities analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of research reports. Needham & Company LLC boosted their target price on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Mizuho upgraded Glaukos from a "neutral" rating to an "outperform" rating and upped their price target for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. Stifel Nicolaus raised their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Wells Fargo & Company upped their target price on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Finally, Truist Financial lowered their price target on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a report on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $159.50.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.